Ipsen initiates a share buyback program to cover its new free share allocation plan
Ipsen initiates a share buyback program to cover its new free share allocation plan
Paris (France), 18 June 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 150,000 Ipsen SA shares, or about 0.18% of the share capital, over a period of maximum 2 months. The shares purchased under this agreement will be mainly allocated to cover its new free employee share allocation plan.
This program is made pursuant to the authorization granted by the Combined Shareholders’ Meeting held on 28 May 2019.
Ipsen initiates a share buyback program to cover its new free share allocation plan
Paris (France), 18 June 2019 – Ipsen (Euronext: IPN; ADR: IPSEY), announces today that it has appointed an investment services provider to purchase 150,000 Ipsen SA shares, or about 0.18% of the share capital, over a period of maximum 2 months. The shares purchased under this agreement will be mainly allocated to cover its new free employee share allocation plan.
This program is made pursuant to the authorization granted by the Combined Shareholders’ Meeting held on 28 May 2019.
Related Press Releases

IPSEN – Buy-back programme – Art 5 of MAR – Week 45 – 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England...

IPSEN – Buy-back programme – Art 5 of MAR – Week 44 – 2023

Ipsen updates on QM-1114 regulatory process

IPSEN – Buy-back programme – Art 5 of MAR – Week 38 – 2023

Ipsen nominates Pascal Touchon to its Board of Directors as new independent director

Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer

IPSEN – Buy-back programme – Art 5 of MAR – Week 28 – 2023

Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U.
